Technology | Quality Assurance (QA) | July 10, 2019

IBA Launches Monte Carlo Patient QA for Varian Halcyon at AAPM 2019

New SciMoCa Monte Carlo patient QA enables fast and efficient quality assurance accuracy for Varian Halcyon in addition to all other major radiation therapy systems

IBA Launches Monte Carlo Patient QA for Varian Halcyon at AAPM 2019

July 10, 2019 — IBA announced the launch of the latest functionality of the SciMoCa Monte Carlo Patient QA solution at the 61st annual American Association of Physicists in Medicine (AAPM) annual meeting, July 14-18 in San Antonio, Texas. The new release of SciMoCa provides what IBA calls the first and only worldwide commercial Monte Carlo Patient QA for the Varian Halcyon System.

Healthcare professionals can now verify all Halcyon treatment plans independently, accurately, and with an automated and efficient workflow. The fast Monte Carlo dose calculation enables highly accurate results even for the most challenging cases like non-coplanar stereotactic body radiation therapy (SBRT), and in particular for indications with tissue inhomogeneity like lung and head & neck treatments.

Monte Carlo is the gold standard for dose calculation accuracy in treatment planning. With SciMoCa, the accuracy of Monte Carlo is now available for independent secondary dose calculation and patient QA (quality assurance) as well, allowing users to verify the most advanced treatment plans with an equally robust and fast QA solution. SciMoCa is used clinically for all standard linear accelerator (linac) types, for the Accuray CyberKnife and TomoTherapy/Radixact, and is now also compatible with Varian Halcyon.

The high-quality beam models for SciMoCa are created linac-specific for customers applying dedicated processes, expert tools and experience. This process allows an independent verification of the commissioning data and the TPS model, providing an additional level of peace of mind about the accuracy of the machine and TPS commissioning. This is particularly valuable for pre-commissioned treatment machines like Halcyon.

The SciMoCa software is manufactured by Radialogica LLC and globally distributed by IBA Dosimetry.

For more information: www.iba-dosimetry.com

Related Content

#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 Professor David Sebag-Montefiore (Image courtesy of the University of Leeds)

Professor David Sebag-Montefiore (Image courtesy of the University of Leeds)

News | Radiation Therapy | April 07, 2020
April 7, 2020 — An intern...
Eclipse v16 has received CE mark and is 510(k) pending
News | Proton Therapy | April 06, 2020
April 6, 2020 — Driven by its Intelligent Cancer Care approach in developing new solutions that use advanced technolo
Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | April 03, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new
Rising concerns over radiation overexposure teamed with a growing focus on improving the quality of patient care are two key drivers of today’s radiation dose management market. 

Rising concerns over radiation overexposure teamed with a growing focus on improving the quality of patient care are two key drivers of today’s radiation dose management market. 

Feature | Radiation Dose Management | April 02, 2020 | By Melinda Taschetta-Millane
Rising concerns over...
A new framework from an international team of experts aims to help protect patients and providers, and conserve protective equipment for frontline healthcare workers #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Prostate Cancer | March 30, 2020
March 30, 2020 — In the wake of the COVID-19 pan
Women are more likely to be cured of cancer by radiotherapy but the side effects are worse.

Women are more likely to be cured of cancer by radiotherapy but the side effects are worse. Image by Mark Kostich

News | Radiation Therapy | March 30, 2020
March 30, 2020 — Women undergoing radiotherapy for
Novel scanners may open door for prognostic assessment in patients receiving cochlear implants

Iva Speck, MD, explains research showing that novel, fully digital, high-resolution positron emission tomography/computed tomography imaging of small brain stem nuclei can provide clinicians with valuable information concerning the auditory pathway in patients with hearing impairment. The research is featured in The Journal of Nuclear Medicine (read more at http://jnm.snmjournals.org/content/current). Video courtesy of Iva Speck, University Hospital Freiburg, Germany.

News | PET-CT | March 26, 2020
March 26, 2020 — Novel, fully digital, high-resolution...
Age‐standardized, delay‐adjusted overall cancer incidence rates for 2012 through 2016 are illustrated among males and females by racial/ethnic group

Age‐standardized, delay‐adjusted overall cancer incidence rates for 2012 through 2016 are illustrated among males and females by racial/ethnic group. Racial/ethnic groups are mutually exclusive. Data for the non‐Hispanic American Indian/Alaska Native (AI/AN) population are restricted to Indian Health Service Purchased/Referred Care Delivery Area (PRCDA) counties. API indicates Asian/Pacific Islander. Chart courtesy of ACS Journals 

News | Radiation Oncology | March 16, 2020
March 16, 2020 — The Ann...